The Bath & Body Works NOligarchy Profile
C
O
N
C
E
R
N
I
N
G
Bath & Body Works scores 46.53 out of 100 on the NOligarchy scale — meaning the closer to zero, the worse the behavior. That number places a $7.29 billion retail fragrance giant just above the middle of its peer group, sitting above a sector average of 40.8. The company’s regulatory record is now its strongest pillar; the weight dragging the score toward zero is a CEO pay gap and a shareholder payout machine that has little parallel in the sector.
Current Pillar Scores
Political Access
53.9
Wealth Extraction
6.5
Playing by the Rules
100.0
Score history — 24 quarters
Tier bands show where each quarter's score falls — no numeric y-axis needed. The dashed ring marks the year-over-year comparison point. Tap any quarter but the first to see its pillar breakdown.
•
Political Access Grade: 53.93/100. From Q4 2024 through Q3 2026 (8 quarters — the two-year tracking period), Bath & Body Works channeled $350,000 into federal lobbying, touching everything from chemical safety rules to tariff policy. The company runs no Political Action Committee (PAC) — confirmed at zero — though $3,500 in executive donations to federal campaigns is recorded for the period.
•
Wealth Extraction Grade: 6.47/100. This is the most damaging number in the profile. A chief executive whose three-year average compensation runs more than 1,300 times the median worker’s annual earnings, hundreds of millions in stock buybacks, and a steady dividend stream to shareholders tell the story of a company that chose to richly reward those at the top of the capital structure while the people staffing its stores saw little of that wealth flow their way.
•
Playing by the Rules Grade: 100/100. Bath & Body Works carries no recorded violations or fines during the two-year tracking period. That is a genuinely clean two-year file.
Bath & Body Works ranks 3rd out of 5 companies in the Health and personal care retailers sector, with a NOligarchy score of 46.53 against a sector average of 40.8. That edges above the mean — but the sector is pulled down sharply by the poorest performers. Measured against the two companies above it, Bath & Body Works still trails on accountability. This is middle of the pack, not a clean bill. For higher-scoring places to shop, see the Better Alternatives section below.
The Bottom Line: A Billion-Dollar Payout Machine Hiding Behind a Thin Lobbying File
Bath & Body Works generated $7.29 billion in annual revenue, according to SEC EDGAR 10-K (CIK 0000701985). In its two most recently reported fiscal years, it handed $802 million back to shareholders through stock buybacks — buying back its own shares to deliberately reduce shares outstanding, inflate per-share metrics, and trigger executive performance bonuses — on top of another $344 million in dividends. Meanwhile, the median Bath & Body Works employee earned less than $9,603 in a year — a figure that, spread across twelve months, amounts to less than $800 a month before taxes. The company’s lobbying operation is modest by Fortune 500 standards, but its wealth extraction machinery is not: the gap between what the CEO collected and what the person folding lotion sets on a retail shelf took home is among the starkest findings in this sector.
Spending to Stay in the Room
Bath & Body Works spent $350,000 on federal lobbying from Q4 2024 through Q3 2026, filing with both the House of Representatives and the Senate across the two-year period, according to Senate Lobbying Disclosure Act (LDA) disclosures. That averages roughly $43,750 per quarter — not enormous by Washington standards, but steady and purposeful. During that span, lobbyists filed contacts with the House and Senate 41 times each — roughly once every 12 business days for each chamber.
FEDERAL CONTACT LOG
HOUSE OF REPRESENTATIVES
41
≈ every 12th business day
SENATE
41
≈ every 12th business day
2 federal bodies named in federal lobbying filings · 2024-Q4–2026-Q3
Between 2024-Q4 and 2026-Q3, Bath & Body Works was named in lobbying filings reaching 2 federal bodies — from HOUSE OF REPRESENTATIVES to SENATE.
The issue portfolio reads like a map of Bath & Body Works’ most pressing business risks. Lobbyists filed eight disclosures each on chemicals and chemical industry concerns, law enforcement and organized retail crime, trade and tariff policy, consumer safety and products, and taxation. The chemicals docket is not abstract: Bath & Body Works sells candles, soaps, and personal care products loaded with fragrance compounds and synthetic ingredients that sit squarely in the crosshairs of federal chemical management regulation. Any tightening of rules on what can go into a three-wick candle or a hand sanitizer directly threatens the company’s supply chain and product formulations.
On organized retail crime, lobbyists filed under law enforcement and crime, citing both the Combating Organized Retail Crime Act of 2023 — introduced in the House as H.R. 895 and in the Senate as S. 140 — each referenced in filings. These bills, still in progress at last filing, would create a federal task force and new criminal penalties targeting coordinated shoplifting rings. For a specialty retailer with hundreds of mall-based stores, shrink from organized theft is a real margin problem, and the company’s lobbyists made sure Congress heard about it across multiple quarters.
Trade and tariff filings tracked issues of international trade and tariff policy — a direct signal of Bath & Body Works’ exposure to import costs on raw materials and finished goods sourced outside the United States. Lobbyists also filed under consumer issues and data privacy, reflecting the retail industry’s broad concern about state-level and federal privacy legislation that would reshape how companies collect and use customer data from loyalty programs and digital storefronts.
The taxation docket cited domestic manufacturing tax incentives and, explicitly, An act to provide for reconciliation pursuant to title II of H. Con. Res. 14 — the legislation that became Public Law 119-21 on July 4, 2025. Lobbyists cited this bill five times across filings, making it the single most cited legislation in Bath & Body Works’ disclosures during the period. The bill was enacted — meaning lobbyists were engaged on live legislation with real stakes as it moved through Congress.
Rail safety appeared in Q4 2024 filings, citing the Railway Safety Act of 2023 (S. 576, still in progress) and the RAIL Act (H.R. 1633, still in progress). A fragrance retailer lobbying on rail safety may seem out of place, but it reflects supply chain reality: Bath & Body Works moves product through freight rail, and major derailments involving hazardous materials put the entire retail sector on notice about logistics vulnerability.
Bath & Body Works hired two outside lobbying firms, including OGR, which also lobbies for AT&T, Nike Inc, Tapestry Inc, and Verizon — giving that vendor a direct window into the priorities of multiple large corporate clients simultaneously.
Shared Lobbying Exposure
Bath & Body Works
client
OGR
lobbying firm
AT&T
also a client
Nike Inc
also a client
Tapestry Inc
also a client
+1 more
clients
Why it matters: the same firm argues Bath & Body Works’s case and its rivals’ — one hire buys a web of shared access that can’t be seen from outside. This network worsens Bath & Body Works’s political-access score (see methodology for the exact factor).
The company runs no corporate PAC, and Federal Election Commission (FEC) PAC Data confirms zero PAC spending for the period. Executive donations of $3,500 to federal campaigns are on record — a negligible sum. The political access footprint here is the lobbying spend, not campaign cash.
Five of Bath & Body Works’ lobbyists previously held senior government positions, according to Lobbying Disclosure Act (LDA) filings. Jennifer Daulby served as Chief of Staff to Rep. Rodney Davis and in multiple House counsel and legislative roles. Stanton Bullock served as Chief of Staff to Senator Daniel Moynihan. Gordon Taylor served as Chief of Staff, Legislative Director, and Counsel to Rep. Chris John. Michael Buchanan served as Chief of Staff of the House Republican Conference. Alissa Clees served as a Scheduler to Senator Ben Nelson. These are not entry-level congressional staffers — they are people with direct relationships inside the committees and leadership offices that write the rules Bath & Body Works is paying to influence.
A $12.6 Million CEO Package, a $9,603 Median Worker, and $802 Million for Wall Street
The single most damaging number in this profile is not the lobbying spend. It is this: the median Bath & Body Works employee earned $9,602.99 in the most recently reported fiscal year, according to the company’s own SEC DEF 14A filing. That is not a yearly salary for a comfortable life — that is $800 a month before taxes, the kind of paycheck that forces workers to choose between rent and groceries.
Against that figure, the CEO pay ratio stands at 1317:1, the 3-year average of Compensation Actually Paid, as disclosed in the same SEC DEF 14A. The CEO’s three-year average package was about $12.6 million. The person at the top of the corporate structure collected — averaged across three years, accounting for equity payouts as they actually landed — more than thirteen hundred times what the person at the bottom of the payroll received. That is not a rounding error. That is a structural decision about whose labor the company values.
The Shareholder Payout. In fiscal years 2024 and 2025 combined, Bath & Body Works spent $802 million buying back its own stock, according to SEC filing disclosures. Each buyback is a deliberate reduction in shares outstanding that inflates per-share metrics and triggers executive performance bonuses — a mechanism that overwhelmingly benefits the wealthiest shareholders and the executives whose bonuses are tied to earnings-per-share targets. Over the same two fiscal years, the company paid out an additional $344 million in dividends. Combined, that is $1.146 billion channeled to capital owners in just two fiscal years — all while the company generated $7.29 billion in annual sales.
The Missed Raise. The company’s SEC proxy filing does not disclose total employee headcount — which means a precise per-worker raise calculation cannot be computed. What can be said plainly: $802 million in buybacks over two fiscal years is a deliberate choice. That money existed. It was real cash. The company decided to use it to reduce its share count rather than increase earnings for the workers whose labor generated it.
The Dividend Factor. Bath & Body Works did not abandon traditional investor payouts in favor of buybacks — it ran both simultaneously. The company paid $177 million in dividends in fiscal 2024 and $167 million in fiscal 2025, on top of $401 million in buybacks each year. That means the company’s leadership chose to operate two parallel shareholder return programs at the same time. The data shows they were not forced to choose between investors and workers — they simply prioritized the former.
Executive Bonuses. The buyback program and the CEO pay gap are not unrelated. When Bath & Body Works buys back its own stock and reduces the number of shares outstanding, earnings per share rises automatically — even if total company earnings stay flat. Many executive compensation packages tie performance bonuses directly to Earnings Per Share (EPS) growth. The same executives who approved the $802 million in buybacks are the same executives whose pay packages benefit when those buybacks cause per-share metrics to climb. The 1317:1 ratio is not just a gap — it is the output of a system the executives at the top designed and then ran.
A Clean Record on the Public Docket
Bath & Body Works carries no recorded violations or regulatory penalties between Q4 2024 and Q3 2026 — the full two-year tracking period covered by this profile. The Good Jobs First violation tracker, which aggregates federal and state enforcement actions, shows no fines matched to this company during that period.
A clean two-year file is worth acknowledging. Bath & Body Works ranks 3rd out of 5 companies in the Health and personal care retailers sector — and on this pillar alone, it outperforms. This two-year period is a fraction of the company’s full docket on the source site; readers can review the broader historical record there. No public subsidy data is recorded for Bath & Body Works during this period, so no public-money-versus-fines contrast is available here.